GLP-1 receptor agonists and related therapeutics represent a major category in the pharmaceutical treatment of obesity and metabolic health conditions. This list focuses on publicly traded companies developing, manufacturing and distributing weight loss medications, including large pharmaceutical firms, biotech companies pursuing novel mechanisms of action and specialty providers supporting drug delivery and patient access.
Amgen is a global pioneer in biotechnology, creating innovative therapies that address serious illnesses and improve global health outcomes.
Eli Lilly and Company innovates medicines to improve lives globally, with a focus on diabetes, oncology, and neuroscience.
Viking Therapeutics develops innovative therapies for metabolic and endocrine disorders, focusing on obesity and liver diseases.
Global healthcare leader Novo Nordisk specializes in diabetes and obesity treatments, driving innovation to combat serious chronic diseases.
Hims & Hers Health, Inc. is a leading telehealth platform offering personalized health and wellness solutions, including prescription medications and over-the-counter products
BioAge Labs develops therapies targeting metabolic aging, focusing on obesity treatments like azelaprag to enhance healthspan.
Metsera develops innovative long-acting oral and injectable therapies targeting obesity and metabolic diseases using proprietary peptide technology.
Weight loss drugs represent a pharmaceutical market segment focused on treatments for obesity and metabolic health. The category encompasses GLP-1 receptor agonists, which mimic hormones that regulate appetite and blood sugar, alongside other therapeutic approaches targeting weight management through different biological pathways.
GLP-1-based medications work by slowing digestion, reducing appetite and improving insulin sensitivity. Clinical applications extend beyond weight reduction to include treatment of type 2 diabetes, cardiovascular disease prevention and other metabolic conditions. Regulatory agencies evaluate expanded indications as clinical trial data broadens understanding of these drugs' health impacts.
The market includes large pharmaceutical companies developing and commercializing GLP-1 therapies, biotech firms pursuing novel mechanisms of action, contract manufacturers scaling production capacity, and specialty pharmacy distributors managing patient access. Companies also focus on drug delivery innovations, combination therapies and next-generation formulations designed to improve efficacy or reduce side effects.
Weight loss therapeutics matter as a market theme because obesity affects a substantial portion of the global population, creating sustained demand for effective treatments. The sector intersects with broader themes in longevity and preventive medicine, as metabolic health influences long-term disease risk. Patent timelines, manufacturing scalability, insurance coverage decisions and competitive positioning shape the commercial dynamics for companies operating in this space.
Join top talent at the world's most respected institutions, companies, and venture capital funds.
